

OSE Immunotherapeutics reinforces its Clinical Team with the Appointment of Iris Pauporté as Clinical Project Director

Nantes, Paris, September 15, 2016 - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a biotechnology company developing immunotherapies of activation and regulation in immuno-oncology, auto-immune diseases and transplantation, today announces the appointment of Iris Pauporté as Clinical Project Director to reinforce the team's scientific expertise.

OSE immunotherapeutics reinforces its clinical team with the appointment of Iris Pauporté as Clinical Project Director for the clinical development of Tedopi[®], an innovative combination of neoepitopes developed in immuno-oncology. Iris will be leading the international registration Phase 3 clinical trial with Tedopi[®], an innovative combination of neoepitopes developed in immuno-oncology in advanced lung cancer (NSCLC). She will also be involved in the preparation of a Phase 2 clinical trial considered in 2017 with Tedopi[®] combined with a checkpoint inhibitor, and in exploring Tedopi[®] in other cancer indications.

"We are very pleased to welcome Iris in our team. She brings significant expertise in clinical research and a network of opinion leaders in oncology and immuno-oncology. She will contribute to the development of our portfolio of products in immuno-oncology, ranging from research to the registration phase, with Effi-DEM, our new generation checkpoint inhibitor in preclinical stage and Tedopi[®] in Phase 3 registration clinical trial", commented Alain Chatelin, Medical Director at OSE Immunotherapeutics.

Iris Pauporté holds a PhD in molecular biology and has more than 20 years' experience in biomedical and clinical research, both in the pharmaceutical industry and at the French National Cancer Institute. Her expertise in coordinating large-scale scientific programs, coupled with her established relationships with many of the opinion leaders in oncology and immuno-oncology are major assets for the development of OSE Immunotherapeutics' programs in immuno-oncology. Iris contributed to outstanding research projects and is a co-author of numerous publications in prestigious scientific journals.

ABOUT OSE IMMUNOTHERAPEUTICS

Our ambition is to become a world leader in activation and regulation immunotherapies

OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.

The company has a balanced portfolio of first-in-class products with a diversified risk profile ranging from clinical phase 3 registration trials to R&D:

- **Tedopi®**, a combination of **10 optimized neo-epitopes** to induce specific T activation in immuno-oncology - **currently in registration Phase 3 trial advanced NSCLC HLA A2+ patients EU /US** - Orphan Status in the US - **registration expected in 2019**
- **FR104**, CD28-antagonist in immunotherapy - **Phase 1 trial completed** - targets autoimmune diseases and transplantation - **licensed to J&J** to pursue clinical development
- **Effi-7**, interleukin receptor 7 antagonist - **in preclinical development** for inflammatory bowel diseases and other autoimmune diseases
- **Effi-DEM**, new generation checkpoint inhibitor targeting the **SIRP- α receptor on the strategic CD47/SIRP- α pathway** - **in preclinical development** for immuno-oncology
- **R&D**: candidates targeting new receptors in immuno-oncology

The portfolio's blockbuster potential gives OSE Immunotherapeutics the ability to enter into global agreements at different stages of development with major pharmaceutical players, such as the one signed for FR104 with the J&J Group.

Immunotherapy is a highly promising and growing market. By 2023 Immunotherapy of cancer could represent nearly 60% of treatments against less than 3% at present * and the projected market is estimated at \$ 67 billion in 2018 **.

There are more than 80 autoimmune diseases that represent a significant market including major players in the pharmaceutical industry with sales upper 10 billion \$ for the main products. The medical need is largely unmet and requires the provision of new innovative products involved in the regulation of the immune system.

*Citi Research Equity

**BCC Research

Since September 1st, 2016, the new company's headquarters are located on: 22, boulevard Benoni Goullin, 44200 Nantes, France

Contacts

OSE Immunotherapeutics

Dominique Costantini, CEO
dominique.costantini@ose-immuno.com
 Mob +33 6 13 20 77 49

Maryvonne Hiance, Vice-Présidente
maryvonne.hiance@ose-immuno.com
 Mobile : 33 (0) 680 060 183

Alexis Peyroles, DGD, Operations, Finance & BD
alexis.peyroles@ose-immuno.com
 Mob : +33 6 11 51 19 77

Bernard Vanhove, DGD, R&D, Collaborations scientifiques
Bernard.vanhove@ose-immuno.com
 Mob: +33 6 75 41 40 08

Contacts media

Citigate Dewe Rogerson
 Laurence Bault
laurence.bault@citigate.fr
 +33 1 53 32 84 78

Alize RP

Florence Portejoie & Caroline Carmagnol
oseimmuno@alizerp.com
 +33 6 47 38 90 04

Consilium Strategic Communications

Chris Gardner / Matthew Neal / Hendrik Thys
OSEImmuno@consilium-comms.com
 +44 (0) 20 3709 5700

Rx Communications Group, LLC

Melody Carey
mcarey@rxir.com
 + 1 917-322-2571

Acorelis

Gilles Petitot
 Mobile : 33 (0) 620 27 65 94
gilles.petitot@acorelis.com

Forward-looking statements

This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.

These forward-looking statements include statements typically using conditional and containing verbs such as "expect", "anticipate", "believe", "target", "plan", or "estimate", their declensions and conjugations and words of similar import.



Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance.

This press release includes only summary information and should be read with the OSE Immunotherapeutics Reference Document filed with the AMF on 8 June 2016 under the number R.16-052, the consolidated financial statements and the management report for the fiscal year 2015, as well as the Merger Document registered with the AMF on 26 April 2016 under number E.16-026, all available on the OSE Immunotherapeutics' website.

Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.